Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | ESR1 | P03372 | 4/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28668485 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL525225 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL525223 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL3313118 | 1.00 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL11498883 | 0.96 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL5241027 | 0.96 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL10603415 | 0.96 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL809368 | 0.96 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Iodide SCHEMBL10825874 | 0.96 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Methane SCHEMBL7931585 | 0.96 | TDP1 (0.86) | TDP1CYP3A4ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215150-A1 | CARBONATE-EPOXY COPOLYMER, CURABLE CARBONATE COMPOSITION, AND MANUFACTURING METHOD OF FORMING CARBONATE-CONTAINING THERMOSET | Swancor Innovation & Incubation Co., Ltd. (TW) | 2025-07-03 | — | — | US | claimed |
| EP-4578889-A1 | CARBONATE-EPOXY COPOLYMER, CURABLE CARBONATE COMPOSITION, AND MANUFACTURING METHOD OF FORMING CARBONATE-CONTAINING THERMOSET | Swancor Innovation & Incubation Co., Ltd. (TW) | 2025-07-02 | — | — | EP | claimed |
| CN-119432196-A | Breathable epoxy seal primer for concrete and preparation method thereof | 长弢新材料(孝感)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-113336717-B | Process for preparing oxazolecarboxylic acid esters | 江西天新药业股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117486740-A | Novel method for efficiently synthesizing chiral alpha-amino acid derivative by asymmetric reduction addition reaction of transition metal catalytic imine | 华东理工大学 | 2024-02-02 | — | — | CN | claimed |
| CN-116041315-A | Chemiluminescent probe for detecting Vanin-1 as well as preparation method and application thereof | 中国药科大学 | 2023-05-02 | — | — | CN | claimed |
| CN-112079679-B | Asymmetric total synthesis method of sex pheromone (R, Z) -21-methyl-8-thirty-five carbene of longicorn | 塔里木大学 | 2022-10-11 | — | — | CN | claimed |
| CN-113336717-A | Process for preparing oxazole carboxylic acid esters | 江西天新药业股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-108559090-B | Waterborne epoxy modified acrylic resin and preparation method thereof | 中山大桥化工集团有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-104558008-B | A kind of method for the intermediate for synthesizing paricalcitol | 陕西师范大学 | 2017-12-05 | — | — | CN | claimed |
| EP-1072589-B1 | Process for producing lycopene and intermediate thereof | SUMITOMO CHEMICAL CO (JP) | 2005-11-09 | — | — | EP | claimed |
| EP-1080082-B1 | INTERMEDIATES FOR THE SYNTHESIS OF EPOTHILONES AND METHODS FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | claimed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | claimed |
| US-6350878-B1 | BASIFICATION AND IODINATION OF ALDEHYDE | NOVARTIS AG (CH) | 2002-02-26 | — | — | US | claimed |
| US-6331652-B1 | Process for producing lycopene and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| EP-1080082-A1 | INTERMEDIATES FOR THE SYNTHESIS OF EPOTHILONES AND METHODS FOR THEIR PREPARATION | Novartis AG (CH) | 2001-03-07 | — | — | EP | claimed |
| EP-1072589-A2 | Process for producing lycopene and intermediate thereof | Sumitomo Chemical Company, Limited (JP) | 2001-01-31 | — | — | EP | claimed |
| WO-1999059985-A1 | INTERMEDIATES FOR THE SYNTHESIS OF EPOTHILONES AND METHODS FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1999-11-25 | — | — | WO | claimed |
| EP-0835254-B1 | OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE | SYNTHELABO (FR) | 1999-09-01 | — | — | EP | claimed |
| US-5843975-A | Oxazolidinone derivatives, their preparation and therapeutical use | SYNTHELABO (FR) | 1998-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | ACHE 3927/4885TDP1 3303/4885CYP3A4 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.